Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 1, 2005, Pages 76-89

  Boni, Joseph P ^a   Leister, Cathie ^a   Bender, Gregor ^a   Fitzpatrick, Virginia ^a   Twine, Natalie ^a   Stover, Jennifer ^a   Dorner, Andrew ^a   Immermann, Fred ^a   Burczynski, Michael E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RAPAMYCIN; RNA; TEMSIROLIMUS;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BODY SURFACE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; COVARIANCE; DIARRHEA; DISEASE SEVERITY; DNA MICROARRAY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG SAFETY; FEMALE; FEVER; GENETIC TRANSCRIPTION; HEADACHE; HEMATOCRIT; HUMAN; HUMAN CELL; HYBRIDIZATION; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFECTION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE DRUG DOSE; MYALGIA; NAIL COLOR; NUCLEOTIDE SEQUENCE; PAPULAR SKIN DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; THROMBOCYTOPENIA; XEROSTOMIA;

ADULT; AGED; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEUKOCYTES, MONONUCLEAR; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHARMACOGENETICS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; THROMBOCYTOPENIA;

EID: 11344271046     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.08.025     Document Type: Article

References (27)

1. J.J. Gibbons, C. Discafani, R. Peterson, R. Hernandez, J. Skotnicki, P. Frost The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract] Proc Am Assoc Cancer Res 40 1999 301
2. K. Yu, L. Toral-Barza, C. Discafani, W.-G. Zhang, J. Skotnicki, P. Frost mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 2001 249 258
3. B. Georerger, K. Kerr, C.-B. Tang, K.-M. Fung, B. Powell, L.N. Sutton Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 2001 1527 1532
4. L. Dudkin, M.B. Dilling, P.J. Cheshire, F.C. Harwood, M. Hollingshead, S.G. Arbuck Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 2001 1758 1764
5. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, R. Petersen Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 1998 10314 10319
6. Y. Shi, J. Gera, L. Hu, J. Hsu, R. Bookstein, W. Li Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 2001 5027 5034
7. P.K. Vogt PI3-kinase, mTOR, protein synthesis and cancer Trends Mol Med 7 2001 482 484
8. M. Atkins, M. Hidalgo, W.M. Stadler, T. Logan, J. Dutcher, G. Hudes Randomized phase II study of multiple dose levels of CCI-779, a novel mTOR kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
9. A. Lampen, Y. Zhang, I. Hackbarth, L.Z. Benet, K.F. Sewing, U. Christians Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine J Pharmacol Exp Ther 285 1998 1104 1112
10. M. Sattler, F.P. Guengerich, C.H. Yun, U. Christians, K.F. Sewing Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 1992 753 761
11. E.F. Petricoin III, J.L. Hackett, L.J. Lesko, R.K. Puri, S.I. Gutman, K. Chumakov Medical applications of microarray technologies: a regulatory science perspective Nat Gen 32 2002 474 479
12. L.J. van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
13. D.A. Wigle, I. Jurisica, N. Radulovich, M. Pintilie, J. Rossant, N. Liu Molecular profiling of non-small cell lung cancer and correlation with disease-free survival Cancer Res 62 2002 3005 3008
14. B.N. Swanson Delivery of high quality biomarker assays Dis Markers 18 2002 47 56
15. J.C. Rockett, M.E. Burczynski, A.J. Fornace, P.C. Herrmann, S.A. Krawetz, D.J. Dix Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells Toxicol Appl Pharmacol 194 2004 189 199
16. N.C. Twine, J.A. Stover, B. Marshall, G. Dukart, M. Hidalgo, W. Stadler Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma Cancer Res 63 2003 6069 6075
17. C.J. Punt, J. Boni, U. Bruntsch, M. Peters, C. Thielert Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors Ann Oncol 14 2003 931 937
18. S.L. Beal L.B. Sheiner NONMEM user's guides 1992 NONMEM Project Group, University of California at San Francisco San Francisco (CA)
19. SAS Institute Inc SAS language reference, version 8 1999 SAS Institute Inc Cary (NC)
20. S.M. Pai, U.A. Shukla, T.H. Grasela, C.A. Knupp, R. Dolin, F.T. Valentine Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex J Clin Pharmacol 32 1992 242 247
21. A. Agresti An introduction to categorical data analysis A Wiley-Interscience publication 1996 John Wiley & Sons Hoboken (NJ). p. 34-44.
22. D.J. Lockhart, H. Dong, M.C. Byrne, M.T. Follettie, M.V. Gallo, M.S. Chee Expression monitoring by hybridization to high-density oligonucleotide arrays Nat Biotechnol 14 1996 1675 1680
23. A.A. Hill, E.L. Brown, M.Z. Whitley, G. Tucker-Kellogg, C.P. Hunter, D.K. Slonim Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls Genome Biol 2 2001 RESEARCH0055
24. J. Parke, N. Holford, B. Charles A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models Comput Methods Programs Biomed 59 1999 19 29
25. E. Ette Stability and performance of a population pharmacokinetic model J Clin Pharmacol 37 1997 486 495
26. Gene Expression Omnibus Web site. Available from: URL: http://www.ncbi.nlm.nih.gov/projects/geo/gds/gds_browse.cgi. Accessed Aug 24, 2004.
27. E.B. Cunningham An inositolphosphate-binding immunophilin, IPBP12 Blood 94 1999 2778 2789